login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
IMMUNEERING CORP - CLASS A (IMRX) Stock News
NASDAQ:IMRX -
US45254E1073
-
Common Stock
5.75
USD
+0.15 (+2.68%)
Last: 8/29/2025, 8:00:02 PM
5.75
USD
0 (0%)
After Hours:
8/29/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMRX Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
- Mentions:
PTIX
AEMD
EQ
SLQT
...
Top stock movements in today's session.
11 days ago - By: Chartmill
- Mentions:
PTIX
COTY
AEMD
SLQT
...
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
5 days ago - By: Immuneering Corporation
Immuneering Announces Closing of $25 Million Private Placement
5 days ago - By: Immuneering Corporation
Immuneering Announces Closing of $25 Million Private Placement
6 days ago - By: Zacks Investment Research
- Mentions:
LLY
REGN
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
7 days ago - By: Immuneering Corporation
- Mentions:
LLY
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
7 days ago - By: Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
11 days ago - By: Benzinga
- Mentions:
PTIX
AEMD
THAR
APM
...
12 Health Care Stocks Moving In Thursday's Intraday Session
11 days ago - By: Chartmill
- Mentions:
GRO
DRD
BLND
AEMD
...
There are notable gap-ups and gap-downs in today's session.
11 days ago - By: Benzinga
- Mentions:
NBY
AEMD
SCNI
EVOK
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 days ago - By: Immuneering Corporation
Immuneering Announces $25 Million Private Placement
11 days ago - By: Immuneering Corporation
Immuneering Announces $25 Million Private Placement
18 days ago - By: The Motley Fool
Immuneering Posts Narrower Loss in Q2
18 days ago - By: Chartmill
- Mentions:
FOSL
RRGB
COHR
CDXS
...
Curious about the stocks that are showing activity after the closing bell on Wednesday?
18 days ago - By: Immuneering Corporation
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
18 days ago - By: Immuneering Corporation
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
2 months ago - By: Immuneering Corporation
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
2 months ago - By: Immuneering Corporation
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
3 months ago - By: Immuneering Corporation
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
3 months ago - By: Immuneering Corporation
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
3 months ago - By: Immuneering Corporation
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
3 months ago - By: Immuneering Corporation
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
3 months ago - By: Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Please enable JavaScript to continue using this application.